Literature DB >> 17482850

Prevalence of temporomandibular disorders in fibromyalgia and failed back syndrome patients: a blinded prospective comparison study.

Ramesh Balasubramaniam1, Reny de Leeuw, Hua Zhu, Robert B Nickerson, Jeffrey P Okeson, Charles R Carlson.   

Abstract

OBJECTIVES: The objective of this study was to determine the prevalence of temporomandibular disorders (TMD) and evaluate psychosocial domains in patients with fibromyalgia (FM) compared with patients with failed back syndrome (FBS). STUDY
DESIGN: The study included 51 (32 FM and 19 FBS) adult patients who were administered orofacial pain and psychological questionnaires before a clinical examination. Presence of TMD was diagnosed according to the Research Diagnostic Criteria for TMD.
RESULTS: Fifty-three percent of the FM patients reported having face pain compared with 11% of the FBS patients. Of those FM patients who reported face pain, 71% fulfilled the criteria for a diagnosable TMD. FM patients had significantly higher subscale scores for somatization, obsessive-compulsive, medication used for sleep, and fatigue compared with FBS patients. Eighty-seven percent of the FM patients reported a stressful event and 42.3% had symptoms indicating posttraumatic stress disorder.
CONCLUSION: The high prevalence of TMD and psychosocial dysfunction among FM patients suggests wide-reaching dysregulation of autonomic and hypothalamic-pituitary-adrenal axis functions.

Entities:  

Mesh:

Year:  2007        PMID: 17482850     DOI: 10.1016/j.tripleo.2007.01.012

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  14 in total

1.  The development and psychometric validation of the central sensitization inventory.

Authors:  Tom G Mayer; Randy Neblett; Howard Cohen; Krista J Howard; Yun H Choi; Mark J Williams; Yoheli Perez; Robert J Gatchel
Journal:  Pain Pract       Date:  2011-09-27       Impact factor: 3.183

2.  Perceived helpfulness of treatments for myofascial TMD as a function of comorbid widespread pain.

Authors:  Vivian Santiago; Karen G Raphael
Journal:  Clin Oral Investig       Date:  2019-01-08       Impact factor: 3.573

3.  Longitudinal Multilevel Modeling of Facial Pain, Muscle Tension, and Stress.

Authors:  A G Glaros; J M Marszalek; K B Williams
Journal:  J Dent Res       Date:  2016-01-12       Impact factor: 6.116

Review 4.  Systematic review of the multidimensional fatigue symptom inventory-short form.

Authors:  Kristine A Donovan; Kevin D Stein; Morgan Lee; Corinne R Leach; Onaedo Ilozumba; Paul B Jacobsen
Journal:  Support Care Cancer       Date:  2014-08-22       Impact factor: 3.603

5.  Further validation of a model of fibromyalgia syndrome in the rat.

Authors:  Paul G Green; Pedro Alvarez; Robert W Gear; Dennis Mendoza; Jon D Levine
Journal:  J Pain       Date:  2011-04-09       Impact factor: 5.820

6.  Temporomandibular disorder and comorbid pain conditions.

Authors:  Pei Feng Lim; William Maixner; Asma A Khan
Journal:  J Am Dent Assoc       Date:  2011-12       Impact factor: 3.634

Review 7.  Management of fibromyalgia syndrome in 2016.

Authors:  Akiko Okifuji; Jeff Gao; Christina Bokat; Bradford D Hare
Journal:  Pain Manag       Date:  2016-06-16

Review 8.  Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain.

Authors:  Lars Arendt-Nielsen; Søren T Skou; Thomas A Nielsen; Kristian K Petersen
Journal:  Curr Osteoporos Rep       Date:  2015-08       Impact factor: 5.096

9.  Subgrouping patients with fibromyalgia according to the results of the Fibromyalgia Impact Questionnaire: a replication study.

Authors:  Elena P Calandre; Jocelyne Garcia-Carrillo; Juan M Garcia-Leiva; Fernando Rico-Villademoros; Rocío Molina-Barea; Carmen M Rodriguez-Lopez
Journal:  Rheumatol Int       Date:  2010-05-20       Impact factor: 2.631

10.  The influence of emotional state on the masticatory muscles function in the group of young healthy adults.

Authors:  Stocka Anna; Kuc Joanna; Sierpinska Teresa; Golebiewska Maria; Wieczorek Aneta
Journal:  Biomed Res Int       Date:  2015-03-26       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.